Background. Although the so-called intact parathyroid hormone (iPTH) assay detects not only true 1-84 PTH (1-84PTH) but also large C-terminal PTH fragments, it remains inconclusive whether the 1-84PTH assay is more useful in clinical practice. Previous studies have shown that the results of these two PTH assays in dialysis patients are closely correlated. Methods. Chronic dialysis patients whose plasma iPTH levels were >400 pg/ml were selected for inclusion in the present study. Following a 4 week wash-out time during which all vitamin D administration was halted, maxacalcitol was intravenously injected at the end of dialysis sessions three times per week for 24 weeks, at an initial dosage of 10 mg. Results. Ninety-seven patients with secondary hyperparathyroidism were included in our analysis. Their serum calcium levels were elevated from the start levels while phosphate levels remained unchanged. The plasma 1-84PTH levels constantly declined throughout the 24 weeks. Although the patients' plasma 1-84PTH and iPTH levels were closely correlated with each other both at the beginning of the study and after 24 weeks of maxacalcitol therapy, the ratio of 1-84PTH/iPTH consistently decreased throughout the study period (P<0.01). The changes in the ratio were significantly correlated with changes in serum calcium levels. Conclusions. Twenty-four weeks of intravenous maxacalcitol injection therapy significantly reduced the 1-84PTH/iPTH ratio. Estimated 1-84PTH levels from iPTH levels using a conversion formula obtained before the treatment were 21.0±20.4% higher than measured 1-84PTH levels after the therapy. Thus, iPTH measurement has a potential risk to overestimate 1-84PTH levels when evaluating the efficacy of maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
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Introduction
Parathyroid function is one of the most commonly used non-invasive indicators of bone metabolism in dialysis patients. Thus, in routine clinical nephrology practice today, the so-called 'intact parathyroid hormone' (iPTH) assay system is commonly applied to estimate both parathyroid function and bone turnover status [1] . This iPTH assay measures not only the true 1-84 PTH (1-84PTH) but also the large C-terminal PTH fragments. Moreover, 7-84PTH [2, 3] , which seems to be a component of the large C-terminal fragments, demonstrates antagonistic actions against 1-84PTH [4] [5] [6] .
Thus, a novel assay system that detects only 1-84PTH has been developed [3] . However, whether the measurement of 1-84PTH is really useful in clinical practice remains inconclusive. A previous study reported that the ratio of 1-84PTH/(iPTH À 1-84PTH) accurately reflects bone metabolism [7] , while other clinical studies provided negative results [8] [9] [10] [11] . Since much larger-scale studies would be necessary to reach any final conclusion, we do not intend to argue the usefulness of the 1-84PTH/(iPTH-1-84PTH) ratio for the prediction of bone metabolism in this manuscript.
Apart from the question of the usefulness of the 1-84PTH/(iPTH À 1-84PTH) ratio in clinical practice, previous research has shown that it is the plasma 1-84PTH levels, and not the 1-84PTH þ large C-terminal PTH fragment levels, that represent parathyroid function in target organs like bone. However, clinical studies have shown that 1-84PTH and iPTH levels are closely correlated with each other in dialysis patients [7, 10, 11] . In other words, although there are a few exceptional cases, the ratio of 1-84PTH/iPTH is generally distributed over a quite narrow range in dialysis patients. Therefore, the estimation of 1-84PTH levels from iPTH levels does not seem to pose serious problems in the majority of cases. In fact, the iPTH assay has been applied to estimate bone metabolism in dialysis patients and the obtained levels did indeed show a fairly good correlation [12, 13] . If it is generally acceptable to estimate 1-84PTH levels from the conventional iPTH assay, the usefulness of the 1-84PTH assay will be quite limited in clinical practice.
However, the ratio of these two PTH levels must be stable, regardless of the patient's condition, in order to estimate 1-84PTH levels from iPTH levels. For example, PTH measurement is often performed to evaluate the efficacy of active vitamin D therapy in dialysis patients. If the ratio of 1-84PTH/iPTH changes when the patient undergoes active vitamin D therapy, parathyroid activity will not be accurately evaluated from plasma iPTH levels.
Thus, we attempted a prospective clinical study of treatment with maxacalcitol (22-oxa-calcitriol), a newly developed artificial active vitamin D analogue [14] , for dialysis patients who suffer from progressive secondary hyperparathyroidism and who are refractory to oral vitamin D therapy. The aim of this study was to investigate the influence of maxacalcitol therapy in the estimation of 1-84PTH levels from iPTH levels.
Subjects and methods

Patients
The protocol of the present study was planned following the ethics guidelines of the Declaration of Helsinki. Patients who were undergoing chronic haemodialysis therapy at the facilities of the Niigata Society of Dialysis Complication Research and whose plasma iPTH levels were >400 pg/ml even while being treated with oral vitamin D were included in the study. Exclusion criteria were complication of malignancy or chronic inflammatory diseases, previous continuous ambulatory peritoneal dialysis treatment, kidney transplantation or parathyroidectomy. After approval of the study protocol by the ethics committees of the various medical facilities, the patients were duly informed about the study and only those who gave their written consent to participate were enrolled. Participants were guaranteed the right to freely withdraw from the study at any time.
Methods
The wash-out period, part of the preparation for participating in the study, consisted of ceasing the use of activated vitamin D agents !4 weeks prior to initiation of the study.
Patients whose plasma iPTH levels fell to <400 pg/ml after the wash-out period were not excluded from the study. After completion of the wash-out period, 10 mg maxacalcitol was intravenously injected three times per week at the end of every dialysis session as an initial dosage. Thereafter, the amount of maxacalcitol per injection varied between 2.5 and 15.0 mg, so that the serum calcium concentration would not exceed 11.5 mg/dl. Haemodialysis conditions, including dialysers, dialysate compositions and anticoagulants, remained unchanged throughout the study period. Although we allowed phosphate binders to be used, the dosage for each patient remained unchanged throughout the study period. The goal of the treatment was to maintain iPTH levels of <250 pg/ml. The treatment was continued for the 24 weeks of the study period, unless the goal of the treatment was achieved or unless one of the following described events occurred. The use of other active vitamin D analogues, glucocorticoid agents, bisphosphonates or any other antiosteoporotic agents was prohibited during the study period and it was decided that those who had to use the abovementioned drugs during the study period would be automatically withdrawn. Patients who underwent surgical thyroidectomy or parathyroidectomy were also withdrawn from the study. Maxacalcitol therapy was discontinued when the adjusted serum calcium levels exceeded 11.5 mg/dl. For evaluation, calcium levels (mg/dl) were adjusted by serum albumin levels (g/dl) when they were <4.0 g/dl:
The treatment was also discontinued if any other intolerable events occurred.
Serum calcium, inorganic phosphate, albumin and iPTH levels were monitored at least once every 4 weeks in each dialysis unit. Each physician in charge decided on the appropriate treatment plan based on the data and clinical symptoms of the patient in question. The iPTH levels measured in each dialysis unit were used by each physician in charge to determine the treatment plans; however, they are not shown in this paper. In addition to routine laboratory examinations, blood samples were collected at 0, 6, 12 and 24 weeks after the initiation of the maxacalcitol therapy. These samples were separated into plasma and sera and stored at À80 C. The 1-84PTH, iPTH, bone-specific alkaline phosphatase (bAP) and intact osteocalcin (OC) levels were measured simultaneously from the stored samples for the purposes of this research. The plasma 1-84PTH and iPTH levels were assayed by immunoradiometric assay methods (Scantibodies Laboratory, Inc., Santee, CA, USA) [4] . The intra-assay coefficient of variation (CV%) for 1-84PTH was <5.0% and the interassay CV% for 1-84PTH was <8.0%. The intra-assay CV% for iPTH was <5.0% and the interassay CV% for iPTH was <7.0%. The iPTH data included in this manuscript were obtained from the stored samples only. Serum bAP levels were determined by an enzyme immunoassay (EIA) method (Kokusai Shiyaku, Kobe, Japan) and the intra-assay CV% was <5.0%. The serum OC levels were measured by EIA (Sumitomo Seiyaku Biomedical Co., Ltd, Osaka, Japan) and the intra-assay CV% was found to be <6.0%. All the blood samples mentioned above were collected at 9.00 a.m. on the third day after the last dialysis session.
Statistical analysis
All values are expressed as means±SD and P<0.05 was considered to be statistically significant. A paired t-test was applied to compare the results. Statistical computations were performed using an Apple Macintosh computer type G4 with software Stat View 5.0 (SAS Institute Inc., Cary, NC, USA).
Results
The initial participants in the study included 140 patients. During the study period, seven patients withdrew of their own will. No patient began to use glucocorticoid agents, bisphosphonates or antiosteoporotic agents during the study. The dosage of phosphate binders for each patient was not changed throughout the study. Surgical parathyroidectomy was performed in two patients, who were consequently withdrawn from the study. The treatment was discontinued in one patient because of increased itching and in nine patients because of hypercalcaemia that exceeded 11.5 mg/dl. No other complications, including the development of ectopic calcification, were documented. The treatment goal was achieved in 24 patients and maxacalcitol therapy was therefore discontinued prior to completion of the 24 week observation period. The remaining 97 patients received maxacalcitol therapy three times per week for 24 weeks and were periodically evaluated during the study period. The dosage of maxacalcitol remained unchanged from the initial dosage of 10 mg throughout the study period in 51 of these 97 patients. Table 1 summarizes the clinical features of all 97 patients included in the study. Figure 1 shows the effects of maxacalcitol therapy on plasma iPTH levels, which decreased in a timedependent manner. The decline in the first 6 weeks of the study period was the most remarkable, after which the iPTH levels continued to decline steadily. Serum bAP levels decreased consistently throughout the study. In contrast, serum OC levels decreased after a transient elevation in the first 6 weeks. Serum calcium levels were obviously elevated while phosphate levels remained unchanged ( Table 2) .
The change in iPTH levels was analysed by dividing it into the change in w PTH and that in large C-terminal fragments by subtracting the 1-84PTH assay value from iPTH levels (iPTH À 1-84PTH). The plasma 1-84PTH and iPTH levels were closely correlated with Fig. 1 . The effects of maxacalcitol therapy on plasma iPTH levels (pg/ml). A remarkable decline was seen in the first 6 weeks, after which levels continued to decline steadily. each other both at the beginning of the study and after 24 weeks of maxacalcitol therapy ( Figure 2) ; however, 1-84PTH showed a significantly larger decrement than iPTH in this 24 week period (51.8±26.5% vs 46.2±29.2%; P<0.0001). The plasma 1-84PTH levels declined consistently over the 24 week study period. The plasma levels of (iPTH À 1-84PTH) declined rapidly in the first 6 weeks and then remained almost unchanged up to the 24th week ( Figure 3 ). The ratio of 1-84PTH/iPTH levels decreased consistently throughout the study period (Figure 4) . Finally, the change in the ratio significantly correlated with the change in serum calcium levels before and after maxacalcitol treatment ( Figure 5 ).
Discussion
High dose vitamin D treatment is used in the treatment of uraemic hyperparathyroidism. PTH measurement is necessary to evaluate the efficacy of active vitamin D Fig. 2 . The relationship between plasma 1-84PTH and iPTH levels. (A) Before the maxacalcitol therapy and (B) after 24 weeks of maxacalcitol therapy. Plasma 1-84PTH and iPTH levels were closely correlated with each other both at the beginning of the study and after 24 weeks of maxacalcitol therapy, however, the regression line was found to differ between these two measurement points. Fig. 4 . The effect of maxacalcitol therapy on the ratio of 1-84PTH / iPTH. The ratio consistently decreased throughout the study period. The ratio at the 24th week was significantly lower than that before treatment. Fig. 3 . The effect of maxacalcitol therapy on plasma 1-84PTH and (iPTH À 1-84PTH) levels. Plasma 1-84PTH levels consistently declined throughout the 24 weeks of observation, while the plasma (iPTH À 1-84PTH) levels declined rapidly in the first 6 weeks, then remained almost unchanged up to the 24th week.
therapy and the assay system must be reliable for impartial judgment. Plasma 1-84PTH and iPTH levels have been found to be closely correlated in dialysis patients with a relatively homogeneous background [7, 10, 11] . Moreover, previous studies revealed that the correlations between iPTH and bone metabolic marker or bone histomorphometry were as close as those between 1-84PTH and bone metabolic markers [11] or bone histomorphometry [9] . In the present study, the close correlation between iPTH and 1-84PTH was confirmed to exist both before and after the administration of maxacalcitol therapy ( Figure 2 ). Therefore, it seems acceptable to apply the iPTH assay to estimate 1-84PTH levels in a cross-sectional study. However, the regression line differed between measurements taken before and after maxacalcitol therapy. This can be attributed to the fact that the ratio of 1-84PTH/iPTH decreased in a time-dependent manner with the progression of maxacalcitol therapy (Figure 4) . Therefore, we cannot estimate 1-84PTH levels from measured iPTH levels using the same conversion formula before and after maxacalcitol treatment. For an example, a conversion formula of: 1-84PTH ðpg=mlÞ ¼ 0:648 Â iPTH þ 36:951 ðpg=mlÞ was given by a simple regression assay before the treatment (Figure 2A ). When this conversion formula was applied after 24 weeks of maxacalcitol therapy, the 1-84PTH levels estimated from iPTH levels were 286±172 pg/ml. However, actually measured 1-84PTH levels after the therapy were 241±169 pg/ml (Figure 3) , giving an error of 21.0±20.4% when it was defined as:
That is, the iPTH level overestimated the 1-84PTH level by 21.0% after 24 weeks of maxacalcitol therapy when a conversion formula obtained before the therapy was applied. This error is obviously too great to be attributable to intra-assay variations. Thus, the iPTH assay seems to be an inappropriate method for estimating 1-84PTH levels in a longitudinal study, such as a study to evaluate the efficacy of active vitamin D therapy in patients with secondary hyperparathyroidism.
The mechanism that mediates changes in 1-84PTH/iPTH levels remains unclear. While we have no evidence that maxacalcitol directly affected the PTH ratio, serum calcium levels seem to be implicated. The change in the 1-84PTH/iPTH ratio was significantly correlated with the change in serum calcium levels before and after maxacalcitol therapy ( Figure 5 ). This result is consistent with a previous report that found an altered ratio of circulating 1-84PTH to (iPTH À 1-84PTH) levels by the change of extracellular calcium levels [15] [16] [17] . Because the serum calcium levels became elevated in most of our patients after maxacalcitol therapy, the average value of the 1-84PTH/iPTH ratio appeared to decrease. However, serum calcium levels did not appear to be correlated with1-84PTH levels or 1-84PTH/iPTH ratios in this study. Thus, the influence of serum calcium levels seemed to be not quite crucial. Further investigations might reveal other factors that also affect the ratio.
It was previously assumed that maxacalcitol suppressed parathyroid function without hypercalcaemic action, however, some studies have reported that maxacalcitol shows a calcaemic effect on dialysis patients [18, 19] . Our data confirm these earlier clinical findings that maxacalcitol appears not to differ from conventional active vitamin D analogues with regard to calcium metabolism in dialysis patients. A rather interesting finding was that no remarkable change was induced in serum phosphate levels by the maxacalcitol therapy. Note that the use of phosphate binder was unchanged in all 97 patients and the dosage of maxacalcitol injected was unchanged in 51 subjects. An additional study is necessary to determine why maxacalcitol therapy did not raise serum phosphate levels.
In conclusion, intravenous maxacalcitol injection therapy was performed in patients with uraemic secondary hyperparathyroidism. The drop in plasma PTH levels was predominantly caused by a decrease in plasma 1-84PTH levels, while the levels of (iPTH À 1-84PTH) were less changed. The ratio of 1-84PTH/iPTH decreased with the progression of the maxacalcitol therapy. This change might partly implicate elevated serum calcium levels. Estimated 1-84PTH levels Fig. 5 . The relationship between changes in serum calcium levels (Ca 24/0W) and changes in the 1-84PTH/iPTH ratio (1-84PTH/ iPTH À 24/0W) by maxacalcitol therapy. Ca 24/0W ¼ (serum calcium levels after 24 weeks of maxacalcitol therapy)/(serum calcium levels before maxacalcitol therapy). 1-84PTH/iPTH 24/0W ¼ (the ratio of plasma 1-84PTH/iPTH levels after 24 weeks of maxacalcitol therapy)/(the ratio of 1-84PTH/iPTH levels before maxacalcitol therapy). Changes in the ratio were significantly correlated with changes in serum calcium levels. from iPTH were significantly higher than measured 1-84PTH levels after the maxacalcitol therapy. Thus, iPTH assay has a potential risk to overestimate 1-84PTH levels when evaluating the efficacy of maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
